Assessment of Helicobacter pylori positive infected patients according to Clarithromycin resistant 23S rRNA, rpl22 associated mutations and cyp2c191, 2, *3 genes pattern in the Early stage of Gastritis.

Atena Abedi Maghami, Ashraf Mohabati Mobarez, Abbas Yadegar, Maryam Nikkhah, Amir Sadeghi, Saber Esmaeili

Abstract read

In one paragraph

Article in BMC research notes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Atena Abedi MaghamiDepartment of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Al-E Ahmad Exp., Tehran, Iran.

Ashraf Mohabati MobarezDepartment of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Al-E Ahmad Exp., Tehran, Iran. mmmobarez@modares.ac.ir.

Abbas YadegarFoodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Maryam NikkhahDepartment of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.

Amir SadeghiGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical, Sciences, Tehran, Iran.

Saber EsmaeiliNational Reference Laboratory of Plague, Tularemia and Q Fever, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveClarithromycin resistant Helicobacter pylori (CAM-R) is the main cause of standard triple therapy eradicating failure. Proton pump inhibitors (PPIs) directly pose bacteriocidic activity and prepare the optimum condition for Clarithromycin's best function. In counter with Poor metabolizer subjects, Homozygote Extensive Metabolizers have well characterized by treatment failure. Eventually, determination of CAM-R profile and estimation of PPIs metabolization rate support clinicians in better prescription. So, we explored Helicobacter pylori'mutations in 23S rRNA and rpl22 resistant genes, and cyp2c19 *1, *2, *3 allele variations, and PPIs metabolization patterns in patients, consequently the results reported to the physician.

resultsSixteen out of 96 patients considered to be CAM-R Helicobacter pylori. A2143C (1/16), rpl22 insertion (16/16), and GTG deletion (2/16) recorded in CAM-R strains. P450 2C19 human genotyping demonstrated that the highest proportion of the H. pylori- positive strains infected patients 43/61(70.49%) categorized in Homozygote extensive metabolizer class. The rest (12/61)19.67% classified as Poor metabolizers, and 6/61(9.83%) distinct from Heterozygote extensive metabolizer group. Proportion of poor metabolizers and Heterozygote extensive metabolizer phenotypes between CAM-R strains mentioned to be 10/16(62.5%), and 6/16(37.5%). Cross points between the most frequently distributed allele in CAM-R strains indicated 81.25% for *2, and

Indexed as

Aryl Hydrocarbon HydroxylasesGastritisHelicobacter InfectionsHelicobacter pyloriAmoxicillinAnti-Bacterial AgentsClarithromycinCytochrome P-450 CYP2C19Drug Therapy, CombinationHumansMutationProton Pump InhibitorsRibosomal ProteinsRNA-Binding ProteinsRNA, Ribosomal, 23SAmoxicillinAnti-Bacterial AgentsAryl Hydrocarbon HydroxylasesClarithromycinCYP2C19 protein, humanCytochrome P-450 CYP2C19Proton Pump InhibitorsRibosomal ProteinsRNA-Binding ProteinsRNA, Ribosomal, 23SRPL22 protein, humanClarithromycin resistantHelicobacter pyloriHeterozygote extensive metabolizerHomozygote extensive metabolizerPoor metabolizer

Identifiers

PMID36284359

DOI10.1186/s13104-022-06227-5

PMCPMC9594930

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.